Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
34 studies found for:    Open Studies | "Carcinoma, Ductal, Breast"
Show Display Options
Rank Status Study
1 Recruiting Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer
Condition: Carcinoma, Ductal, Breast
Interventions: Procedure: Biopsy before and after three weeks of study treatment;   Drug: Paclitaxel;   Drug: lapatinib;   Drug: trastuzumab
2 Not yet recruiting Evaluation of Percutaneous Treatment by Cryoablation of Unifocal Invasive Breast Carcinoma in Menopausal Women With Indication of Lumpectomy
Conditions: Carcinoma, Ductal, Breast;   Menopausal
Intervention: Device: Cryoablation
3 Recruiting Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1
Condition: Invasive Ductal Breast Carcinoma
Interventions: Drug: Carboplatin;   Drug: Abraxane;   Drug: MPDL3280A;   Procedure: Surgery;   Drug: Anthra
4 Recruiting Lumpectomy Followed By Intraoperative Electron Radiation Therapy (IOERT)
Conditions: Invasive Ductal Breast Cancer;   Carcinoma Breast Stage I
Intervention: Radiation: Intraoperative Electron Radiotherapy
5 Recruiting Clinical Outcome of Chemotherapy in Surgical Patients With Infiltrating Ductal Carcinoma of Breast
Condition: Breast Cancer
Interventions: Drug: Single agent of cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate;   Drug: cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate (CDEFM);   Drug: Placebo
6 Recruiting Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer
Condition: Ductal Breast Carcinoma In Situ
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Nelipepimut-S Plus GM-CSF Vaccine;   Biological: Sargramostim
7 Recruiting MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ
Condition: Ductal Breast Carcinoma In Situ
Interventions: Procedure: Magnetic Resonance Imaging;   Procedure: Therapeutic Conventional Surgery;   Procedure: Therapeutic Surgical Procedure;   Radiation: Radiation Therapy;   Drug: Endocrine Therapy;   Other: Quality-of-Life Assessment;   Other: Laboratory Biomarker Analysis;   Other: Cytology Specimen Collection Procedure
8 Not yet recruiting G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
Conditions: Carcinoma, Ductal, Breast;   Breast Cancer;   Breast Neoplasm
Interventions: Drug: G1T38;   Drug: Fulvestrant
9 Recruiting Sentinel Lymph Node Identification in the Axilla of Women With Breast Cancer Using Ultrasound and Iron Injection
Conditions: Breast Neoplasm;   Carcinoma, Ductal, Breast;   Carcinoma, Intraductal, Noninfiltrating
Interventions: Procedure: Iron-tracer guided axillary ultrasound and biopsy;   Drug: Iron tracer
10 Not yet recruiting Conjugated Estrogens/Bazedoxifene in Treating Patients With Ductal Carcinoma in Situ Undergoing Surgery
Conditions: Ductal Breast Carcinoma In Situ;   Postmenopausal
Interventions: Drug: Conjugated Estrogens/Bazedoxifene;   Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Other: Placebo;   Procedure: Quality-of-Life Assessment;   Other: Questionnaire Administration
11 Recruiting Breast Cancer WEight Loss Study (BWEL Study)
Conditions: Ductal Breast Carcinoma in Situ;   Breast Carcinoma
Interventions: Other: Health Education Program;   Other: Weight Loss Intervention
12 Recruiting Targeted Intraoperative Radiotherapy United States (TARGIT-US) Registry Trial
Conditions: Malignant Neoplasm of Breast;   Breast Diseases;   Ductal Breast Carcinoma
Intervention: Radiation: Intraoperative radiation therapy (IORT)
13 Recruiting Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response to Neoadjuvant Chemotherapy
Conditions: Invasive Ductal Breast Cancer;   Tubular Breast Cancer;   Mucinous Breast Cancer;   Inflammatory Breast Cancer
Interventions: Drug: Paclitaxel;   Drug: Cisplatin;   Drug: Epirubicin;   Drug: Cyclophosphamide;   Drug: 5-fluoruracil
14 Recruiting Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive Breast Cancer Patients
Conditions: Tubular Breast Cancer;   Mucinous Breast Cancer;   Invasive Ductal Breast Cancer;   Inflammatory Breast Cancer
Interventions: Drug: Paclitaxel;   Drug: Cisplatin;   Drug: Gonadotropin-releasing hormone agonist;   Drug: Letrozole
15 Recruiting BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer
Conditions: Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Invasive Ductal Breast Carcinoma;   Progesterone Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: PI3K inhibitor BYL719;   Drug: letrozole;   Other: laboratory biomarker analysis;   Other: pharmacological studies
16 Not yet recruiting Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
Conditions: Breast Cancer;   Ductal Carcinoma;   Invasive Breast Carcinoma;   Invasive Ductal Breast Carcinoma
Interventions: Biological: Talimogene laherparepvec;   Drug: Paclitaxel
17 Not yet recruiting Denosumab as an add-on Neoadjuvant Treatment (GeparX)
Conditions: Breast Cancer Female NOS;   Tubular Breast Cancer Stage II;   Mucinous Breast Cancer Stage II;   Invasive Ductal Breast Cancer;   HER2 Positive Breast Cancer;   Inflammatory Breast Cancer;   Tubular Breast Cancer Stage III
Interventions: Drug: Denosumab;   Drug: nab-Paclitaxel;   Drug: Epirubicin;   Drug: Cyclophosphamide;   Drug: Carboplatin;   Drug: Trastuzumab;   Drug: Pertuzumab
18 Recruiting A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)
Conditions: Tubular Breast Cancer Stage II;   Tubular Breast Cancer Stage III;   Mucinous Breast Cancer Stage II;   Breast Cancer Female NOS;   Invasive Ductal Breast Cancer;   HER2 Positive Breast Cancer;   Inflammatory Breast Cancer
Interventions: Drug: non-pegylated liposomal doxorubicin;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Epirubicin;   Drug: Cyclophosphamide;   Drug: Pertuzumab;   Drug: Trastuzumab;   Drug: Ferric carboxymaltose
19 Not yet recruiting Oxybutynin Chloride in Managing Hot Flashes
Conditions: Bothered by Hot Flashes;   Breast Carcinoma;   Ductal Breast Carcinoma In Situ;   Lobular Breast Carcinoma In Situ
Interventions: Drug: Oxybutynin Chloride;   Other: Placebo;   Procedure: Quality-of-Life Assessment;   Other: Questionnaire Administration
20 Recruiting Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
Conditions: Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Invasive Ductal Breast Carcinoma;   Invasive Lobular Breast Carcinoma;   Recurrent Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: fulvestrant;   Drug: anastrozole

   Previous Page Studies Shown (1-20) Next Page (21-34) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.